Intravitreal versus subtenon triamcinolone acetonide injection for diabetic macular edema: A systematic review and meta-analysis

Current Eye Research

Volumn 37, Issue 12, 2012, Pages 1136-1147

  Qi, Hui Ping ^a   Bi, Sheng ^a   Wei, Shu Qin ^b   Cui, Hao ^a   Zhao, Jing Bo ^c  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MONTREAL   (Canada)

^c HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Diabetic macular edema; Intravitreal; Meta analysis; Subtenon; Triamcinolone acetonide

Indexed keywords

TRIAMCINOLONE ACETONIDE;

CONJUNCTIVA DISEASE; DIABETIC MACULAR EDEMA; DRUG ADMINISTRATION; DRUG EFFICACY; ENDOPHTHALMITIS; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; META ANALYSIS; OPHTHALMOPLEGIA; PERFORATING EYE INJURY; PRIORITY JOURNAL; RETINA DETACHMENT; REVIEW; SUBTENON DRUG ADMINISTRATION; SYSTEMATIC REVIEW; TENON CAPSULE; TREATMENT DURATION; VISUAL ACUITY; VITREOUS HEMORRHAGE;

CLINICAL TRIALS AS TOPIC; DIABETIC RETINOPATHY; GLUCOCORTICOIDS; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULAR EDEMA; TENON CAPSULE; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; VISUAL ACUITY; VITREOUS BODY;

EID: 84870283429     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2012.705412     Document Type: Review

References (47)

1. Klein R, Klein BE, Moss SE et al. The Wisconsin epidemio-logic study of diabetic retinopathy. I V. Diabetic macular edema. Ophthalmology 1984;91:1464-1474. (Pubitemid 15197017)
2. Moss SE, Klein R, Klein BE. Ten-year incidence of visual loss in a diabetic population. Ophthalmology 1994;101:1061-1070. (Pubitemid 24183163)
3. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology 1998;105:998-1003. (Pubitemid 28268322)
4. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report no. 1. Arch Ophthalmol 1985;103:1796-1806.
5. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-1431. (Pubitemid 28405191)
6. Massin P, Bandello F, Garweg JG et al. Safety and effcacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010;33:2399-2405.
7. Early Treatment Diabetic Retinopathy Study Research Group. Focal photocoagulation treatment of diabetic macular edema. Report number 19. Arch Ophthalmol 1995;113:1144-1155.
8. Early Treatment Diabetic Retinopathy Study Research Group. Treatment. Techniques and clinical guidelines for photocoagulation of diabetic macular edema. Report number 2. Ophthalmology 1987;94:761-774.
9. rd, Patz A. Macular edema. A complication of diabetic retinopathy. Surv Ophthalmol 1984;28 Suppl:452-461. (Pubitemid 14076504)
10. Bresnick GH. Diabetic macular edema. A review. Ophthalmology 1986;93:989-997. (Pubitemid 16046114)
11. Lee CM, Olk RJ. Modifed grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results. Ophthalmology 1991;98:1594-1602.
12. Hartley KL, Smiddy WE, Flynn HW Jr et al. Pars plana vitrectomy with internal limiting membrane peeling for diabetic macular edema. Retina (Philadelphia, Pa) 2008;28:410-419. (Pubitemid 351354941)
13. Figueroa MS, Contreras I, Noval S. Surgical and anatomical outcomes of pars plana vitrectomy for diffuse nontrac-tional diabetic macular edema. Retina (Philadelphia, Pa) 2008;28:420-426. (Pubitemid 351354942)
14. PKC-DMES Study Group. Effect of ruboxistaurin in patients with diabetic macular edema: thirty month results of the randomized PKC-DMES clinical trial. Arch Ophthalmol 2007;125:318-324.
15. Nguyen QD, Tatlipinar S, Shah SM et al. Vascular endothe-lial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006;142:961-969.
16. Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005;112:1747-1757.
17. Ciulla TA, Walker JD, Fong DS, Criswell MH. Corticosteroids in posterior segment disease: an update on new delivery systems and new indications. Curr Opin Ophthalmol 2004;15:211-220. (Pubitemid 38638866)
18. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal comparing intravitreal tri-amcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008;115:1447-1459. e1-10.
19. Martidis A, Duker JS, Greenberg PB et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002;109:920-927. (Pubitemid 34465226)
20. Jonas JB. Retinal venous pulsation and glaucoma. Ophthalmology 2005;112:948-9; author reply 949.
21. Lafranco Daffon M, Tran VT, Guex-Crosier Y et al. Posterior sub-Tenon's steroid injections for the treatment of posterior ocular infammation: indications, eff-cacy and side effects. Graefes Arch Clin Exp Ophthalmol 1999;237:289-295. (Pubitemid 29145806)
22. Zamir E, Read RW, Smith RE et al. A prospective evaluation of subconjunctival injection of triamcinolone acetonide for resistant anterior scleritis. Ophthalmology 2002;109:798-805; discussion 805. (Pubitemid 34270142)
23. Bakri SJ, Kaiser PK. Posterior subtenon triamcinolone aceton-ide for refractory diabetic macular edema. Am J Ophthalmol 2005;139:290-294. (Pubitemid 40288274)
24. Toda J, Fukushima H, Kato S. Injection of triamcinolone acetonide into the posterior sub-tenon capsule for treatment of diabetic macular edema. Retina (Philadelphia, Pa) 2007;27:764-769. (Pubitemid 47051774)
25. Inoue M, Takeda K, Morita K et al. Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection. Am J Ophthalmol 2004;138:1046-1048. (Pubitemid 40040025)
26. Jea SY, Byon IS, Oum BS. Triamcinolone-induced intraocular pressure elevation: intravitreal injection for macular edema and posterior subtenon injection for uveitis. Korean J Ophthalmol 2006;20:99-103.
27. Yamamoto Y, Komatsu T, Koura Y et al. Intraocular pressure elevation after intravitreal or posterior sub-Tenon triamcinolone acetonide injection. Can J Ophthalmol 2008;43:42-47. (Pubitemid 351269567)
28. Hirano Y, Ito T, Nozaki M et al. Intraocular pressure elevation following triamcinolone acetonide administration as related to administration routes. Jpn J Ophthalmol 2009;53:519-522.
29. Sakamoto T, Hida T, Tano Y et al.; Committee for Triamcinolone Acetonide for Ocular Disease in Japan. [Survey of triamcinolone acetonide for ocular diseases in Japan]. Nippon Ganka Gakkai Zasshi 2007;111:936-945.
30. Cellini M, Pazzaglia A, Zamparini E et al. Intravitreal vs. subtenon triamcinolone acetonide for the treatment of diabetic cystoid macular edema. BMC Ophthalmol 2008;8:5.
31. Ozdek S, Bahçeci UA, Gürelik G et al. Posterior subtenon and intravitreal triamcinolone acetonide for diabetic macular edema. J Diabetes Complicat 2006;20:246-251.
32. Bonini-Filho MA, Jorge R, Barbosa JC et al. Intravitreal injection versus sub-Tenon's infusion of triamcino-lone acetonide for refractory diabetic macular edema: a randomized clinical trial. Invest Ophthalmol Vis Sci 2005;46:3845-3849. (Pubitemid 44264695)
33. Cardillo JA, Melo LA Jr, Costa RA et al. Comparison of intra-vitreal versus posterior sub-Tenon's capsule injection of tri-amcinolone acetonide for diffuse diabetic macular edema. Ophthalmology 2005;112:1557-1563. (Pubitemid 41725412)
34. Choi YJ, Oh IK, Oh JR, Huh K. Intravitreal versus posterior subtenon injection of triamcinolone acetonide for diabetic macular edema. Korean J Ophthalmol 2006;20:205-209.
35. Takata C, Messias A, Folgosa MS et al. Intravitreal injection versus subtenon infusion of triamcinolone acetonide during cataract surgery in patients with refractory diabetic macular edema. Retina (Philadelphia, Pa) 2010;30:562-569.
36. Yalcinbayir O, Gelisken O, Kaderli B et al. Intravitreal versus sub-tenon posterior triamcinolone injection in bilateral diffuse diabetic macular edema. Ophthalmologica 2011;225:222-227.
37. Browning DJ, Glassman AR, Aiello LP et al.; Diabetic Retinopathy Clinical Research Network. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 2007;114:525-536.
38. Larsson J, Zhu M, Sutter F et al. Relation between reduction of foveal thickness and visual acuity in diabetic mac-ular edema treated with intravitreal triamcinolone. Am J Ophthalmol 2005;139:802-806. (Pubitemid 40614764)
39. Ranta VP, Urtti A. Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling. Adv Drug Deliv Rev 2006;58:1164-1181.
40. Wilson CA, Berkowitz BA, Sato Y et al. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol 1992;110:1155-1159.
41. Zaka-ur-Rab S, Mahmood S, Shukla M et al. Systemic absorption of triamcinolone acetonide after posterior sub-Tenon injection. Am J Ophthalmol 2009;148:414-419.
42. Degenring RF, Jonas JB. Serum levels of triamcinolone acetonide after intravitreal injection. Am J Ophthalmol 2004;137:1142-1143. (Pubitemid 38759374)
43. Kalina PH, Erie JC, Rosenbaum L. Biochemical quantifcation of triamcinolone in subconjunctival depots. Arch Ophthalmol 1995;113:867-869.
44. Rudnisky CJ, Lavergne V, Katz D. Visual acuity after intra-vitreal triamcinolone for diabetic macular edema refractory to laser treatment: a meta-analysis. Can J Ophthalmol 2009;44:587-593.
45. Yilmaz T, Weaver CD, Gallagher MJ et al. Intravitreal tri-amcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review. Ophthalmology 2009;116:902-11; quiz 912.
46. Gillies MC, Islam FM, Larsson J et al. Triamcinolone-induced cataract in eyes with diabetic macular oedema:3-year prospective data from a randomized clinical trial. Clin Experiment Ophthalmol 2010;38:605-612.
47. Kocabora MS, Yilmazli C, Taskapili M et al. Development of ocular hypertension and persistent glaucoma after intravitreal injection of triamcinolone. Clin Ophthalmol 2008;2:167-171.